These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 26145170)

  • 1. Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists.
    Madonna R; Cocco N; De Caterina R
    Cardiovasc Drugs Ther; 2015; 29(5):469-79. PubMed ID: 26145170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Strategies in the Treatment of Pulmonary Arterial Hypertension.
    Madonna R; Cocco N
    Curr Drug Targets; 2016; 17(7):817-23. PubMed ID: 26201488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin receptor antagonists for pulmonary arterial hypertension: an overview.
    Raja SG
    Cardiovasc Ther; 2010 Oct; 28(5):e65-71. PubMed ID: 20406243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Endothelin receptor antagonists in pulmonary arterial hypertension].
    Tokgöz HC; Can MM; Kaymaz C
    Anadolu Kardiyol Derg; 2010 Sep; 10 Suppl 2():9-15. PubMed ID: 20819750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension.
    Chaumais MC; Guignabert C; Savale L; Jaïs X; Boucly A; Montani D; Simonneau G; Humbert M; Sitbon O
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):13-26. PubMed ID: 25421754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-based pharmacologic management of pulmonary arterial hypertension.
    Benedict N; Seybert A; Mathier MA
    Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin receptor antagonists in pulmonary arterial hypertension.
    Channick RN; Sitbon O; Barst RJ; Manes A; Rubin LJ
    J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):62S-67S. PubMed ID: 15194180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan.
    Beghetti M
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():16-24. PubMed ID: 16919006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical therapies for pulmonary arterial hypertension.
    Pulido T; Zayas N; de Mendieta MA; Plascencia K; Escobar J
    Heart Fail Rev; 2016 May; 21(3):273-83. PubMed ID: 26791159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Guignabert C; Günther S; Girerd B; Jaïs X; Algalarrondo V; Price LC; Savale L; Sitbon O; Simonneau G; Humbert M
    Pharmacol Ther; 2014 Feb; 141(2):172-91. PubMed ID: 24134901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
    Correale M; Ferraretti A; Monaco I; Grazioli D; Di Biase M; Brunetti ND
    Vasc Health Risk Manag; 2018; 14():253-264. PubMed ID: 30323613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pulmonary arterial hypertension: changing approaches to management].
    Sidorenko BA; Preobrazhenskiĭ DV; Batyraliev TA; Belenkov IuN
    Kardiologiia; 2011; 51(1):100-8. PubMed ID: 21626809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.
    Price LC; Howard LS
    Am J Cardiovasc Drugs; 2008; 8(3):171-85. PubMed ID: 18533738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.
    Zheng YG; Ma H; Hu EC; Liu G; Chen G; Xiong CM
    Pulm Pharmacol Ther; 2014 Dec; 29(2):241-9. PubMed ID: 25173912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Review of Randomized Controlled Trials of Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension.
    Kuntz M; Leiva-Juarez MM; Luthra S
    Lung; 2016 Oct; 194(5):723-32. PubMed ID: 27506903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of pulmonary arterial hypertension: role of ambrisentan.
    Barst RJ
    Vasc Health Risk Manag; 2007; 3(1):11-22. PubMed ID: 17583171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin receptor antagonists in pulmonary arterial hypertension.
    Dupuis J; Hoeper MM
    Eur Respir J; 2008 Feb; 31(2):407-15. PubMed ID: 18238950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin receptor antagonists.
    Clozel M; Maresta A; Humbert M
    Handb Exp Pharmacol; 2013; 218():199-227. PubMed ID: 24092342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
    Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
    Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Treatments for Pulmonary Arterial Hypertension: Interpreting Outcomes by Network Meta-analysis.
    Badiani B; Messori A
    Heart Lung Circ; 2016 Jan; 25(1):46-52. PubMed ID: 26233257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.